Latest Order Backlog News

SHAPE Australia Corporation Limited reported a robust half-year performance with a 48.5% rise in net profit and declared a fully franked 14 cent interim dividend, underpinned by strategic acquisition and operational discipline.

Oldfields Holdings reports steady progress in its turnaround strategy, cutting costs and reallocating assets to stronger regions while preparing for a capital raise and potential acquisitions.

Ava Risk Group reports a softer first half with delayed orders impacting revenue, but anticipates a robust recovery in the second half backed by new contracts and a strategic investment.

DXN Limited reported a 63% revenue decline in Q2 FY26 due to project delays but bolstered its future outlook with a $15 million backlog and a strategic joint venture in Indonesia.

Elsight Limited capped 2025 with record quarterly revenue and a substantial US$21.2 million contract, signalling robust growth and expanding global defence engagements heading into 2026.

Elsight has transitioned from development to production with its new Aura communications platform, delivering initial units to a leading defence contractor and expanding its U.S. presence amid a strong financial turnaround in 2025.

Electro Optic Systems has landed a significant €11.4 million contract for its Slinger Counter-Drone systems from a Western European NATO country, boosting its contract backlog to nearly A$400 million. This surge underscores EOS’s growing footprint in the defence sector amid rising drone threats.

Oldfields Holdings navigated a challenging first quarter of FY2026 with tight cash flow and subdued sales but made strategic moves to streamline operations and bolster scaffold order backlogs for growth.

Ava Risk Group reported a 5% revenue increase in FY2025, driven by its Detect segment and a strong sales backlog. The company targets over 20% revenue growth in FY2026, supported by its Aura Ai-X fibre optic sensing technology and strategic global partnerships.

Ava Risk Group reported a solid start to FY2026 with $9 million in Q1 sales orders and a $7.5 million backlog, underpinning its guidance for a profitable first half.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.